Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Tislelizumab for untreated HER2-negative, unresectable advanced gastric or gastroesophageal junction adenocarcinoma

Condition

Cancer

Gastrointestinal tract

1 July 2026

-

Published on 01 Jul 2026
Last Updated on 01 Jul 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Tislelizumab 100 mg/10 mL concentrate for solution for infusion, in combination with fluoropyrimidine and platinum-based chemotherapy, for untreated, unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma with a PD-L1 expression ≥1%.

The decision was based on the acceptable clinical effectiveness and potential cost savings to the healthcare system.

Funding status

Tislelizumab 100 mg/10 mL concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2026.

Clinical indication, subsidy class and MediShield Life claims eligibility for tislelizumab are provided in the Annex.

Guidance_Tislelizumab for untreated HER2-negative, unresectable advanced gastric or gastroesophageal junction adenocarcinoma (1 Jul 2026) [PDF, 196.36 KB]

Back to top